Faron Pharmaceuticals Oy is a Finnish drug discovery and development company focused on acute trauma, cancer and inflammatory diseases. With a pipeline of drug development projects, the company's lead products include Traumakine, a recombinant human IFN beta-1a currently in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS), Clevegen, an immunotherapy candidate designed to prevent tumor growth and metastasis, and D-ARDS, a diagnostic tool to estimate ARDS severity and follow up on ARDS outcomes. Faron Pharmaceuticals Oy collaborates with MediCity unit of Turku University Medical School, and was founded in 2003 in Turku, Finland.